{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:40Z","timestamp":1792783300243,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma Tor Vergata","id":[{"id":"https:\/\/ror.org\/02p77k626","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Somatostatin receptor positron emission tomography (SSTR PET) characterizes receptor expression and supports peptide receptor radionuclide therapy (PRRT) eligibility, whereas [18\u00a0F]fluorodihydroxyphenylalanine ([18\u00a0F]FDOPA) reflects amine-precursor handling. We systematically reviewed incremental diagnostic yield-defined as additional imaging-detected disease rather than demonstrated clinical benefit-and directional discordance between paired [18\u00a0F]FDOPA and [68Ga]Ga-DOTA-peptide PET in well-differentiated intestinal neuroendocrine tumors. PubMed, Scopus, and Web of Science were searched to 26 July 2026. Seven reports representing six diagnostic cohorts and one probable overlapping PRRT companion report were included. Compatible patient-level 2\u2009\u00d7\u20092 tables were reconstructable in four reports; one historical two-patient subgroup was fully concordant. In the three informative cohorts (80 patients), only eight patients were discordant (three [18\u00a0F]FDOPA-only and five DOTA-peptide-only), with different directions across clinically heterogeneous studies; no pooled matched effect was estimated. At lesion level, [18\u00a0F]FDOPA often depicted additional hepatic, peritoneal, nodal, and pulmonary sites, but counts were clustered within patients. Serotonin\/5-hydroxyindoleacetic acid associations were exploratory and did not define a selection threshold. No study established management or survival benefit. PRRT evidence was limited to eight patients. Current evidence supports task-specific interpretation of complementary imaging phenotypes, not routine dual-tracer imaging. [18\u00a0F]FDOPA cannot replace validated SSTR PET for receptor characterization or PRRT eligibility.<\/jats:p>","DOI":"10.1007\/s12149-026-02289-8","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:33:16Z","timestamp":1790145196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incremental diagnostic yield and tracer discordance of [18\u00a0F]FDOPA relative to [68Ga]Ga-DOTA-peptide PET in well-differentiated intestinal neuroendocrine tumors: a systematic review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-8858","authenticated-orcid":false,"given":"Agostino","family":"Chiaravalloti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Schillaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"9","key":"2289_CR1","doi-asserted-by":"publisher","first-page":"e13423","DOI":"10.1111\/jne.13423","volume":"36","author":"A Lamarca","year":"2024","unstructured":"Lamarca A, Bartsch DK, Caplin M, Kos-Kudla B, Kjaer A, Partelli S, et al. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024;36(9):e13423. https:\/\/doi.org\/10.1111\/jne.13423.","journal-title":"J Neuroendocrinol"},{"issue":"9","key":"2289_CR2","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588\u2013601. https:\/\/doi.org\/10.1007\/s00259-017-3728-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2289_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.122.264860","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, et al. SNMMI procedure standard\/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors. J Nucl Med. 2023;64(2):204\u201310. https:\/\/doi.org\/10.2967\/jnumed.122.264860.","journal-title":"J Nucl Med"},{"key":"2289_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-026-00777-5","author":"F Lanfranchi","year":"2026","unstructured":"Lanfranchi F, Lanzolla T, Ravelli I, Arnone A, D\u2019Arienzo D, Frega N, et al. Technical and clinical recommendations for [18F]FDOPA PET\/CT in oncologic applications. Clin Transl Imaging. 2026. https:\/\/doi.org\/10.1007\/s40336-026-00777-5.","journal-title":"Clin Transl Imaging"},{"issue":"7","key":"2289_CR5","doi-asserted-by":"publisher","first-page":"e70220","DOI":"10.1111\/jne.70220","volume":"38","author":"CM Deroose","year":"2026","unstructured":"Deroose CM, Ambrosini V, Hofland J, Kaltsas G, Kjaer A, Lamarca A, et al. Controversies in NEN: an ENETS position statement on the interchangeability of somatostatin receptor PET tracers. J Neuroendocrinol. 2026;38(7):e70220. https:\/\/doi.org\/10.1111\/jne.70220.","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"2289_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/cen.14527","volume":"95","author":"A Piccardo","year":"2021","unstructured":"Piccardo A, Fiz F, Bottoni G, Ugolini M, Noordzij W, Trimboli P. Head-to-head comparison between 18F-DOPA PET\/CT and 68Ga-DOTA peptides PET\/CT in detecting intestinal neuroendocrine tumours: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021;95(4):595\u2013605. https:\/\/doi.org\/10.1111\/cen.14527.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2289_CR7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"1","key":"2289_CR8","first-page":"68","volume":"54","author":"D Putzer","year":"2010","unstructured":"Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, et al. Comparison of 68Ga-DOTA-Tyr3-octreotide and 18F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging. 2010;54(1):68\u201375.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"8","key":"2289_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529\u201336. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009.","journal-title":"Ann Intern Med"},{"issue":"8","key":"2289_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","volume":"35","author":"V Ambrosini","year":"2008","unstructured":"Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35(8):1431\u20138. https:\/\/doi.org\/10.1007\/s00259-008-0769-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2289_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","volume":"36","author":"A Haug","year":"2009","unstructured":"Haug A, Auernhammer CJ, W\u00e4ngler B, Tiling R, Schmidt G, G\u00f6ke B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36(5):765\u201370. https:\/\/doi.org\/10.1007\/s00259-008-1030-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2289_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/cen.14312","volume":"94","author":"E Ouvrard","year":"2021","unstructured":"Ouvrard E, Chevalier E, Addeo P, Sahakian N, Detour J, Goichot B, et al. Intraindividual comparison of 18F-FDOPA and 68Ga-DOTATOC PET\/CT detection rate for metastatic assessment in patients with ileal neuroendocrine tumours. Clin Endocrinol (Oxf). 2021;94(1):66\u201373. https:\/\/doi.org\/10.1111\/cen.14312.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2289_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/RLU.0000000000003450","volume":"46","author":"C Ansquer","year":"2021","unstructured":"Ansquer C, Touchefeu Y, Faivre-Chauvet A, Leux C, Le Bras M, R\u00e9genet N, et al. Head-to-head comparison of 18F-DOPA PET\/CT and 68Ga-DOTANOC PET\/CT in patients with midgut neuroendocrine tumors. Clin Nucl Med. 2021;46(3):181\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000003450.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"2289_CR14","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2967\/jnumed.122.263984","volume":"63","author":"E Ouvrard","year":"2022","unstructured":"Ouvrard E, De Mestier L, Boursier C, Lachachi B, Sahakian N, Chevalier E, et al. 18F-DOPA PET\/CT at the forefront of initial or presurgical evaluation of small-intestine neuroendocrine tumors. J Nucl Med. 2022;63(12):1865\u201370. https:\/\/doi.org\/10.2967\/jnumed.122.263984.","journal-title":"J Nucl Med"},{"issue":"1","key":"2289_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41824-022-00133-6","volume":"6","author":"EB Veenstra","year":"2022","unstructured":"Veenstra EB, Brouwers AH, de Groot DJA, Hofland J, Walenkamp AME, Brabander T, et al. Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy. Eur J Hybrid Imaging. 2022;6(1):12. https:\/\/doi.org\/10.1186\/s41824-022-00133-6.","journal-title":"Eur J Hybrid Imaging"},{"issue":"3","key":"2289_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/RLU.0000000000003447","volume":"46","author":"EB Veenstra","year":"2021","unstructured":"Veenstra EB, de Groot DJA, Brouwers AH, Walenkamp AME, Noordzij W. Comparison of 18F-DOPA versus 68Ga-DOTATOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms. Clin Nucl Med. 2021;46(3):195\u2013200. https:\/\/doi.org\/10.1097\/RLU.0000000000003447.","journal-title":"Clin Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02289-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02289-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02289-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:03:39Z","timestamp":1790190219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02289-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":16,"alternative-id":["2289"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02289-8","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This systematic review used aggregate data from previously published studies and did not involve individual participant data or direct participant contact.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}